News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
GlaxoSmithKline (JOBS) to Pay Actelion Ltd. up to $3.3 Billion for Drug Rights
July 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - GlaxoSmithKline Ltd could pay Swiss company Actelion Ltd up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Mergers & acquisitions
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid
November 3, 2025
·
4 min read
·
Tristan Manalac
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
October 31, 2025
·
3 min read
·
Annalee Armstrong
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
October 31, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes
October 31, 2025
·
2 min read
·
Tristan Manalac
